View AMCP Learn Market Insights Webinar - Best Practice on Wet Macular Degeneration

FINDINGS FROM THE AMCP MARKET INSIGHTS PROGRAM | July, 2024

View AMCP's webinar on strategies to optimize patient outcomes and manage costs in Wet Age-Related Macular Degeneration. 

Neovascular, or wet, age-related macular degeneration (wet AMD) is a significant cause of central visual impairment, contributing to about half of all cases of blindness in Americans aged 50 years and older. The estimated number of individuals affected by wet AMD in the United States is projected to double to 5.4 million between 2010 and 2050. Although there is currently no cure for wet AMD, there are treatment options that slow disease progression. 

In this webinar, key panelists will share insights curated from AMCP's Market Insights program on the patient burden of wet AMD and how payers can best manage it by considering factors such as timeliness of treatment, treatment durability, and cost-effective treatment strategies.

View Now

For more disease state research, view the Market Insights Program.